Significant Ownership of Roivant Sciences Ltd.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Roivant Sciences Ltd. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Keyur Parekh - Keyur Parekh, Authorized Signatory
- Manager location
- London
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Roivant Sciences Ltd. and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Roivant Sciences Ltd.
Significant Ownership of Roivant Sciences Ltd.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IMVT | Immunovant, Inc. | Common Stock, par value $0.0001 per share | 56% | $2,812,776,314 | +$413,666,650 | 113,327,007 | +17% | Roivant Sciences Ltd. | 12 Dec 2025 |
| ABUS | Arbutus Biopharma Corp | Common Shares, without par value | 20% | $127,808,150 | 38,847,462 | 0% | Roivant Sciences Ltd. | 21 Feb 2025 |
Schedules 13D/G Reported by Roivant Sciences Ltd.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.